Stock Taper 
| DATE | TYPE | RATIO |
|---|---|---|
| 2022-07-22 | Reverse | 4:5 |
| 2022-07-19 | Reverse | 4:5 |
| 1991-11-12 | Forward | 2:1 |
| 1986-01-27 | Forward | 2:1 |
| 1983-02-22 | Forward | 2:1 |
| 1980-02-13 | Forward | 2:1 |
GSK plc, founded in 1715 and headquartered in the UK, develops vaccines and medicines across various therapeutic areas through R&D and collaborations, serving global markets.
Arexvy is a blockbuster RSV vaccine for older adults, quickly capturing U.S. market share and highlighting GSK's focus on infectious diseases and high-growth specialty medicines.
GSK's stock saw a significant increase, rising as much as 7%, after the company reported strong third-quarter earnings that surpassed analyst expectations and subsequently raised its full-year 2025 profit forecast. The growth was driven by strong sales in its Specialty Medicines division, particularly in HIV and oncology, as well as its vaccines segment.
GSK announced a landmark decision to invest $30 billion in its US-based research and development and supply chain infrastructure over the next five years. This includes a significant $1.2 billion allocation towards advanced manufacturing, AI, and digital technologies to create next-generation biopharmaceutical facilities.
GSK (NYSE: GSK - Get Free Report) and Eyepoint Pharmaceuticals (NASDAQ: EYPT - Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, analyst recommendations and risk. Valuation and Earnings This table compares GSK and Eyepoint
Candidate selected by GSK utilizes Wave's best-in-class SpiNA design siRNA and triggers a milestone payment to Wave; three additional collaboration programs advancing
GSK and Sanofi offer distinct growth drivers, but stronger earnings estimates, Dupixent momentum and a lower valuation are putting one European drugmaker in focus.
Investment bank Jefferies has kept its ‘buy' rating and 2,500p target on GSK PLC (LSE:GSK, NYSE:GSK), the FTSE 100 drugmaker, after a fireside chat with its chief scientific officer reinforced its view that B7H3 is one of GSK's most underappreciated opportunities. The target implies 35% upside from the prior close of 1,851p, while GSK had a market capitalisation of £74.9 billion.
MRK and Daiichi withdraw an FDA filing for ifinatamab deruxtecan after data falls short, while late-stage studies continue.
MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage pharmaceutical company focused on the discovery and development of small molecule therapeutics derived from its boron chemistry platform, today announced that the Gates Foundation has awarded an extension of funding to support AN2 Therapeutics' research activities under its ongoing tuberculosis (TB) research collaboration with GSK focused on the development of boron-based leucyl-tRNA synthetase (LeuRS).
Overall rating: A-
| PEER | PRICE | |
|---|---|---|
 VRTX | $504.73 | COMPARE |
 BMY | $61.15 | COMPARE |
 CVS | $86.46 | COMPARE |
 MCK | $902.28 | COMPARE |
 SNY | $39.92 | COMPARE |
 HCA | $426.69 | COMPARE |
 ELV | $386.43 | COMPARE |
 CI | $270.53 | COMPARE |
